Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly (NR-COVID19)

Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19

The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients.

A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work from our and other groups suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. In this randomized double blinded case-control trial, the investigators will treat elderly (>70 year old) COVID19 patients with 1 g of nicotinamide riboside (NR-E) or placebo for 2 weeks and investigate if this affects the clinical course of the disease.

Study Overview

• Status: Withdrawn
• Conditions: COVID
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: Nicotinamide riboside

Detailed Description

Currently the number of SARS-CoV-2 positive patients are increasing worldwide and healthcare systems are attempting to cope with the massive pressure that this pandemic results in. Given the highly infectious virus and the relatively high mortality, this pandemic will likely result in many thousand casualties. Interventions are direly needed.

During the early reports of the pandemic it quickly became apparent that mortality was primarily attributed to the elderly population. Indeed, the mortality rate of young adults was around 0.2% while elderly Covid-19 patients displayed a mortality rate of ~20%. Thus, fatality rates increase ~100 fold when comparing young adults to elderly individuals.

A major event in aging is the loss of the central metabolite nicotinamide adenine dinucleotide (NAD+) that appear to be important in the proinflammatory environment that occur during aging. Notably, recent work from our and other groups suggest that aging can be ameliorated by even a short-term treatment of the NAD+ precursor nicotinamide riboside. Nicotinamide riboside has recently been shown to be able to return aging tissues to a younger state even after short term treatment. This vitamin B3- analog is naturally occurring, is readily taken up through oral administration and has been tested in human trials with few side effects. The purpose of this aim is to investigate if nicotinamide riboside can reduce the severity of COVID-19 in patients aged 70 or older.

The elderly population is particularly problematic because long term respirator use for these patients is connected with a substantial mortality risk. Interventions that can keep them from fulminant respiratory failure is therefore of critical importance.

1.2 Study treatment: Nicotinamide riboside Nicotinamide riboside (NR-E, supplied by Elysium Health) is a naturally occurring vitamin B3 analog produced by yeast and found in multiple food products at low concentration. Many organisms including humans cannot produce nicotinamide riboside but have evolved methods to convert this into the central redox modulator NAD+.

The efficacy and safety of nicotinamide riboside has been tested in a number of studies in both healthy controls and in patients suffering from metabolic disease, a risk factor for an adverse outcome of COVID-19 patients. Since this is a natural compound widely found in nature no subjects have yet developed allergic responses to the molecule, and repeated doses of up to 2 g orally per day have demonstrated an acceptable safety profile.

No treatment-emergent adverse events have so far been reported for nicotinamide riboside

1.3 Rationale NAD+ is emerging as a central metabolic molecule involved in multiple age-related pathways including inflammation and metabolic control. Notably, 2 weeks nicotinamide riboside treatment increases metabolic output, normalizes muscle function and reverses hypoxic responses in old mice. Recently, NAD+ has been shown to positively activate the inflammatory response in various tissue and may be involved in polarizing macrophages towards the M1 lineage and facilitate resolution of inflammation. Previously it was shown that SARS-CoV-1 evades activation of the immune response and exogenous activation of macrophages leads to a better outcome of SARS-CoV-1 infection. Thus, activation of elderly macrophages via NAD+ replenishment could be an efficacious strategy in COVID-19 patients. In addition, NAD+ replenishment may facilitate overall greater resilience of elderly patients considering the anti-aging effects of nicotinamide riboside allowing these patients to better cope with infections.

1.4 Rationale for study design and doses The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections. The chosen dosage is 1 g per day given orally. This is lower than 2 g previously given to healthy elderly individuals, however, this particular patient population have not been treated with nicotinamide riboside previously so a slightly lower dose was chosen. In addition, there is data suggesting that NAD+ regulates circadian rhythm and the dose is therefore given in the morning.

The study design is as follows: Elderly patients (>70 years old) seen with suspected COVID-19 at Bispebjerg hospital that are not requiring oxygen therapy are subjected to a COVID-19 test. The patients will be asked if they want to participate in this trial. If the patients agree and if the COVID-19 test is positive the patients will be randomized to either placebo or 1g nicotinamide riboside daily. Previous work has shown an efficacious increase in NAD+ levels combined with better physiological outcomes after 2 weeks treatment in preclinical trials. The investigators will therefore treat patients for 2 weeks total with a primary outcome of the study being hypoxic respiratory failure as defined by needing oxygen therapy. The patients will be evaluated in the ambulatory at day 7 and after the treatment ends at day 14. Follow up in the ambulatory will occur three months after enrollment. If a patient is admitted to the hospital during the treatment period the treatment continues for the full two weeks. To evaluate outcomes, untargeted metabolomics and the NAD-ome will be measured in peripheral blood mononucleated cells (PBMCs) upon enrolment, at day 7 and immediately after the study as well as at follow up three months later. Changes in the epigenetic landscape is a strong biomarker of age and is affected by NAD+ and epigenetic evaluation will be performed in the PBMCs. Next generation machine learning data analysis will be applied to identify predictors of clinical outcome.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen NV, Denmark, 2400
    • Bispebjerg Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Written informed consent
2. Age 70 or older, inclusive at the time of diagnosis.
3. Body mass index between 18-40 kg/m2 (both inclusive) and weight ≥ 40 kg at enrolment.
4. A diagnosis of Covid-19.

Exclusion Criteria:

1. Need for oxygen therapy.
2. Ongoing severe acute respiratory syndrome.
3. Cancer diagnosis within last 5 years.
4. Unwillingness or inability to follow the procedures outlined in the protocol.
5. Concurrent enrollment in another clinical study involving an investigational treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Control; Patients receiving placebo.	Dietary supplement: Placebo; Placebo
Experimental: NR; Patients receiving nicotinamide riboside (NR-E)	Dietary supplement: Nicotinamide riboside; The patients will receive 1 g of nicotinamide riboside or placebo orally every morning for 14 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hypoxic respiratory failure	Hypoxic respiratory failure as defined by need for oxygen therapy	Day 1
Hypoxic respiratory failure	Hypoxic respiratory failure as defined by need for oxygen therapy	Day 7
Hypoxic respiratory failure	Hypoxic respiratory failure as defined by need for oxygen therapy	Day 14
Hypoxic respiratory failure	Hypoxic respiratory failure as defined by need for oxygen therapy	Day 90

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mortality	Overall mortality	Day 1
Mortality	Overall mortality	Day 7
Mortality	Overall mortality	Day 14
Mortality	Overall mortality	Day 90
Sepsis	Sepsis	Day 1
Sepsis	Sepsis	Day 7
Sepsis	Sepsis	Day 14
Sepsis	Sepsis	Day 90
Circulatory failure	Circulatory failure as defined by a need for interventions to support the circulatory system.	Day 1
Circulatory failure	Circulatory failure as defined by a need for interventions to support the circulatory system.	Day 7
Circulatory failure	Circulatory failure as defined by a need for interventions to support the circulatory system.	Day 14
Circulatory failure	Circulatory failure as defined by a need for interventions to support the circulatory system.	Day 90
Days in hospital	Days in hospital	Day 1
Days in hospital	Days in hospital	Day 7
Days in hospital	Days in hospital	Day 14
Days in hospital	Days in hospital	Day 90
NAD levels	Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.	Day 1
NAD levels	Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.	Day 7
NAD levels	Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.	Day 14
NAD levels	Measurements of NAD+ and related metabolite levels by mass spectrometry in whole blood.	Day 90

Collaborators and Investigators

• Sponsor: University of Copenhagen
• Collaborators: Bispebjerg Hospital; Elysium Health

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2020
• Primary Completion (Anticipated): May 1, 2021
• Study Completion (Anticipated): May 1, 2022

Study Registration Dates

• First Submitted: May 22, 2020
• First Submitted That Met QC Criteria: May 27, 2020
• First Posted (Actual): May 29, 2020

Study Record Updates

• Last Update Posted (Actual): September 22, 2022
• Last Update Submitted That Met QC Criteria: September 19, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Antimetabolites; Micronutrients; Hypolipidemic Agents; Lipid Regulating Agents; Vitamins; Vitamin B Complex; Nicotinic Acids; Niacinamide; Niacin
• Other Study ID Numbers: H-20026601

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No